April 18, 2024 — ​​​​The Company generated revenues of $686,205 during this period, driven by strong sales performance of its flagship product, DirectInject-LC™

April 15, 2024 — ​​​​Telescope’s new approach isolates lithium and valuable transition metals from battery recycling feeds.

February 26, 2024 — ​​​​Telescope pairs its DirectInject-LC™ technology with Shimadzu’s chemical analysis instrumentation.

February 15, 2024 — We welcome Henry Dubina as CEO, John Kirincic as CFO, and Deborah Cotter as Corporate Secretary. Jason Hein transitions to CTO.

January 30, 2024 — The Company generated revenues of $1.50 M for a net income of $215,000, exceeding its prior records.

January 23, 2024 — Telescope announces it has filed a provisional patent application on a disruptive new technique to purify lithium carbonate.

December 22, 2023 — The Company generated revenues of $2.82 M, representing an increase of 375% over the previous fiscal year.

December 18, 2023 — Telescope has invented a low-temperature method of generating lithium sulfide from brine-sourced lithium chemicals.

October 30, 2023 — Telescope and Mott plan to develop and commercialize a novel robotic sampling probe for automated chemistry analysis.

August 28, 2023 — Telescope’s first Canadian patent describes a scalable manufacturing process to produce pharmaceutically-relevant indole compounds.

August 3, 2023 — Telescope has granted 800,000 incentive stock options to certain directors of the Company in accordance with the Company’s incentive stock option plan.

June 29, 2023 — The Company generated revenues of $1.01M and a net income of $67,847 in Q3, 2023, representing an increase of 500% in net income over the previous quarter.

We will be out in full force at Canada’s largest chemistry conference this year. CSC 2023 is coming to our hometown of Vancouver, and here’s where catch us!

April 25, 2023 — Just over one year after securing facilities, assembling a team, and outfitting a research laboratory, the Company delivered its first profitable quarter.

February 8, 2023 — Telescope is revenue-positive for a second consecutive quarter. Catch us at a series of upcoming investor events and technical conferences.

January 23, 2023 — Telescope reports revenue in first full year of operation, a new project with Aqualung Carbon Capture, and upcoming events.

November 10, 2022 — Telescope intends to use the net proceeds from the Offering for working capital and general corporate purposes. 

October 31, 2022 — View PR highlights and watch the video on how this project supports Telescope’s goals

October 24, 2022 — Telescope will collaborate with NRCan to build an autonomous, self-driving experimental platform for lithium refinement.

September 6, 2022 — Dr. Sherman brings over thirty years of experience in the scientific instrument industry, including work with Micromeritics Instrument Corporation, ThermoFisher Scientific, and Mettler-Toledo.

September 1, 2022 — We anticipate that our OTCQB listing will provide greater liquidity and a more seamless trading experience for our U.S. shareholders.

August 10, 2022 — We created a proof-of-concept robotic workflow leveraging our proprietary in-situ analytical technology and automation tools.

June 27, 2022 — The Direct Inject Liquid Chromatography (“DILC”) platform is an innovative instrument for real-time, immediate analysis of chemical reactions.

April 29, 2022 — Shareholders elected Prof. Jason Hein, Robert Mintak, James Andrew Robinson, Ali Pejman, and Henry Dubina as directors of the Company.

April 26, 2022 — Henry Dubina, the ex-president and strategic business unit head of Mettler-Toledo Autochem, is expected to be nominated as an independent director of Telescope.

April 25, 2022 — “Telescope Industries” is a division of the Company dedicated to resolving process and manufacturing inefficiencies in the chemical industry. For its first project, Telescope Industries has been engaged by Hatch Ltd., a global engineering, project management, and professional services firm.

March 14, 2022 — Positive results from these studies could warrant preclinical development of Telescope’s proprietary compounds as next-generation psychedelic therapeutics.

March 1, 2022 — Over the past year, we have established a growing intellectual property portfolio on pharmaceutical manufacturing,
increased in-house research capacity and proprietary research platforms, and brought in award winning scientific leadership.

Jan 17, 2022 — This patent represents a key milestone in addressing the impending manufacturing bottleneck for pharmaceutical-grade psilocybin and psychedelic tryptamines.

Nov 29, 2021 — We are excited to have come to this agreement with UBC allowing us freedom to own and continue developing our intellectual property.